Related Experiment Video
Updated: Mar 17, 2026
06:52
Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
Published on: April 28, 2023
2.1K
[Copper metabolism and genetic disorders].
Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 27, 2016
Summary
Copper is essential but toxic in excess. This paper details human copper metabolism, focusing on Menkes disease (copper deficiency) and Wilson disease (copper accumulation), both linked to copper-transporting P-type ATPase defects.
Area of Science:
- Biochemistry
- Human Genetics
- Trace Element Metabolism
Background:
- Copper is an essential trace element vital for human health.
- Both copper deficiency and excess can cause severe health issues.
- Inborn errors of copper metabolism include Menkes disease and Wilson disease.
Purpose of the Study:
- To describe human copper metabolism.
- To outline the clinical features, diagnosis, and treatment of Menkes disease.
- To outline the clinical features, diagnosis, and treatment of Wilson disease.
Main Methods:
- Review of human copper metabolism pathways.
- Analysis of genetic defects in copper transport P-type ATPases (ATP7A and ATP7B).
- Compilation of clinical data, diagnostic criteria, and therapeutic strategies for Menkes and Wilson diseases.
Main Results:
- Menkes disease, an X-linked recessive disorder, results from ATP7A defects causing copper deficiency.
- Wilson disease, an autosomal recessive disorder, results from ATP7B defects causing copper accumulation.
- Defective copper transport P-type ATPases underlie both Menkes and Wilson diseases.
Conclusions:
- Understanding copper metabolism is crucial for diagnosing and managing related disorders.
- Menkes and Wilson diseases highlight the critical role of precise copper homeostasis.
- Effective management strategies for these genetic disorders are essential for patient outcomes.
More Related Videos
11:04Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
Published on: September 7, 2019
10.0K
13:04Atomic Absorbance Spectroscopy to Measure Intracellular Zinc Pools in Mammalian Cells
Published on: May 16, 2019
39.3K
Related Concept Videos
01:20Inborn Errors of Metabolism
990
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
990
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
102
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
102
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
94
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94
01:27Pharmacogenetics of Drug Metabolism: Overview
90
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
90
01:16Drug toxicity: Idiosyncratic Reactions
127
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
127
01:27Principles of Pharmacogenetics: Types of Genetic Variants
73
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
73